COVID-19 Puts the World Health Organization ’s Emergency Use Listing (EUL) to Work

The World Health Organization’s Emergency Use Listing (EUL) provides an approach for assessing medicines, vaccines, and diagnostics that could help address an outbreak classified by the WHO as a Public Health Emergency of International Concern (PHEIC). Robyn Meurant, executive director, regulatory services, IVDs and medical devices for NSF International, describes the EUL as “akin to the U.S. FDA’s Emergency Use Authorization” and says it could help countries that are “without great means to do testing.” Before joining NSF International, Meurant acted both as a professional officer and an advisor to WHO and assisted with the development of the EUL for IVDs in 2014. MD+DI asked Meurant a few questions about the WHO’s EUL and how it could help IVD and device manufacturers respond—and healthcare systems manage—the COVID-19 pandemic.   What is the Emergency Use Listing (EUL) for WHO and how would it pertain to diagnostics manufacturers? Meurant: The World Health Organization’s Emergency Use Listing, or EUL, was developed in 2014 in response to the Ebola outbreak in three west African nations. Akin to the FDA’s Emergency Use Authorization (EUA), it’s an assessment for medicines, vaccines, and devices used to address an outbreak classified by the...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news